US7141244B1
(en)
*
|
1992-03-02 |
2006-11-28 |
Chiron Srl |
Helicobacter pylori proteins useful for vaccines and diagnostics
|
ATE229978T1
(en)
*
|
1994-07-01 |
2003-01-15 |
Chiron Corp |
HELICOBACTER PROTEINS AND VACCINES
|
ES2283012T3
(en)
*
|
1996-01-04 |
2007-10-16 |
Novartis Vaccines And Diagnostics, Inc. |
HELICOBACTER PYLORI BACTERIOFERRITINE.
|
CA2340283A1
(en)
|
1998-08-20 |
2000-03-02 |
Aventis Pasteur Limited |
Nucleic acid molecules encoding pomp91a protein of chlamydia
|
US6686339B1
(en)
|
1998-08-20 |
2004-02-03 |
Aventis Pasteur Limited |
Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
|
EP1105490A1
(en)
|
1998-08-20 |
2001-06-13 |
Aventis Pasteur Limited |
Nucleic acid molecules encoding inclusion membrane protein c of chlamydia
|
US6649370B1
(en)
|
1998-10-28 |
2003-11-18 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
US6607730B1
(en)
|
1998-11-02 |
2003-08-19 |
Aventis Pasteur Limited/Aventis Pasteur Limitee |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
AU3790900A
(en)
|
1998-12-01 |
2000-06-19 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
US20020061848A1
(en)
|
2000-07-20 |
2002-05-23 |
Ajay Bhatia |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
IL143531A0
(en)
|
1998-12-08 |
2002-04-21 |
Corixa Corp |
Polypeptides containing an antigenic portion of a chlamydia antigen, dna sequences encoding said polypeptides and pharmaceutical compositions and vaccines containing the same
|
GB9828000D0
(en)
|
1998-12-18 |
1999-02-10 |
Chiron Spa |
Antigens
|
US7297341B1
(en)
|
1998-12-23 |
2007-11-20 |
Sanofi Pasteur Limited |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
ATE384738T1
(en)
|
1998-12-28 |
2008-02-15 |
Aventis Pasteur |
CHLAMYDIA ANTIGENS, CORRESPONDING DNA FRAGMENTS AND THEIR USES
|
US6808713B1
(en)
|
1998-12-28 |
2004-10-26 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
GB9902555D0
(en)
|
1999-02-05 |
1999-03-24 |
Neutec Pharma Plc |
Medicament
|
AU775695B2
(en)
|
1999-03-12 |
2004-08-12 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
CA2373021A1
(en)
|
1999-05-03 |
2000-11-09 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding dna fragments and uses thereof
|
JP4667694B2
(en)
|
1999-09-20 |
2011-04-13 |
サノフィ、パストゥール、リミテッド |
Chlamydia antigen and corresponding DNA fragments and uses thereof
|
US6632663B1
(en)
|
1999-09-22 |
2003-10-14 |
Aventis Pasteur Limited |
DNA immunization against chlamydia infection
|
EP1240331B1
(en)
|
1999-12-22 |
2010-04-07 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding dna fragments and uses thereof
|
PT2270030E
(en)
|
2000-02-28 |
2012-07-24 |
Novartis Vaccines & Diagnostic |
Heterologous expression of neisserial proteins
|
US20020132994A1
(en)
*
|
2000-04-04 |
2002-09-19 |
Murdin Andrew D. |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
US20020071831A1
(en)
*
|
2000-04-04 |
2002-06-13 |
Murdin Andrew D. |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
EP1278855B1
(en)
|
2000-04-21 |
2008-03-12 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
EP1282718B1
(en)
|
2000-05-08 |
2006-12-20 |
Sanofi Pasteur Limited |
Chlamydia antigens and corresponding dna fragments and uses thereof
|
EP1297005B1
(en)
|
2000-07-03 |
2009-08-26 |
Novartis Vaccines and Diagnostics S.r.l. |
Immunisation against chlamydia pneumoniae
|
GB0024200D0
(en)
*
|
2000-10-03 |
2000-11-15 |
Smithkline Beecham Sa |
Component vaccine
|
US20030059896A1
(en)
*
|
2000-12-21 |
2003-03-27 |
Shire Biochem Inc. |
Novel chlamydia antigens and corresponding DNA fragments
|
US7082569B2
(en)
|
2001-01-17 |
2006-07-25 |
Outlooksoft Corporation |
Systems and methods providing dynamic spreadsheet functionality
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
EP1604688B1
(en)
|
2001-06-05 |
2010-02-03 |
CureVac GmbH |
Stabilised tumour-antigen mRNA with increased G/C-content
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
EP1423142A1
(en)
*
|
2001-08-31 |
2004-06-02 |
Chiron SRL. |
Helicobacter pylori vaccination with a combination of caga, vaca and nap proteins
|
ES2312649T3
(en)
|
2001-12-12 |
2009-03-01 |
Novartis Vaccines And Diagnostics S.R.L. |
IMMUNIZATION AGAINST CHLAMYDIA TRACHOMATIS.
|
DE10162480A1
(en)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
The application of mRNA for use as a therapeutic agent against tumor diseases
|
AU2003235707A1
(en)
*
|
2002-01-18 |
2003-07-30 |
Curevac Gmbh |
Immunogenic preparations and vaccines on the basis of mrna
|
GB0203403D0
(en)
|
2002-02-13 |
2002-04-03 |
Chiron Spa |
Chlamydia cytotoxic-T cell epitopes
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
ES2649048T3
(en)
|
2002-11-01 |
2018-01-09 |
Glaxosmithkline Biologicals S.A. |
Drying procedure
|
EP2279746B1
(en)
|
2002-11-15 |
2013-10-02 |
Novartis Vaccines and Diagnostics S.r.l. |
Surface proteins in neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
CA2520124A1
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of benzazole compounds for immunopotentiation
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
PL1631264T5
(en)
|
2003-06-02 |
2018-09-28 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions based on biodegradable microparticles comprising a diphtheria- and a tetanus toxoid
|
US7350597B2
(en)
*
|
2003-08-19 |
2008-04-01 |
At-Balance Americas Llc |
Drilling system and method
|
JP2007511227A
(en)
*
|
2003-11-21 |
2007-05-10 |
サノフィ パストゥール リミテッド |
Immunity against Chlamydia infection
|
WO2005084306A2
(en)
*
|
2004-03-02 |
2005-09-15 |
Chiron Corporation |
Immunogenic compositions for chlamydia pneunomiae
|
WO2006115509A2
(en)
|
2004-06-24 |
2006-11-02 |
Novartis Vaccines And Diagnostics Inc. |
Small molecule immunopotentiators and assays for their detection
|
EP2612679A1
(en)
|
2004-07-29 |
2013-07-10 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
DE102004042546A1
(en)
*
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Combination therapy for immune stimulation
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
GB0502096D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Purification of streptococcal capsular polysaccharide
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
CN101203529A
(en)
|
2005-02-18 |
2008-06-18 |
诺华疫苗和诊断公司 |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
SI2351772T1
(en)
|
2005-02-18 |
2016-11-30 |
Glaxosmithkline Biologicals Sa |
Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
|
EP2357000A1
(en)
|
2005-10-18 |
2011-08-17 |
Novartis Vaccines and Diagnostics, Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
WO2007081447A2
(en)
|
2005-11-22 |
2007-07-19 |
Novartis Vaccines And Diagnostics, Inc. |
Norovirus and sapovirus antigens
|
CA2637598A1
(en)
|
2006-01-18 |
2007-02-14 |
University Of Chicago |
Compositions and methods related to staphylococcal bacterium proteins
|
ES2536426T3
(en)
|
2006-03-23 |
2015-05-25 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
BRPI0711557A2
(en)
*
|
2006-05-05 |
2011-11-08 |
Perkinelmer Las Inc |
methods for determining an amount of a first analyte in a sample by mass spectroscopy and for screening blood by mass spectroscopy for at least one disorder, and, solid substrate
|
JP2010500399A
(en)
|
2006-08-16 |
2010-01-07 |
ノバルティス アーゲー |
Immunogen from Urinary Pathogenic Escherichia coli
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
KR101621837B1
(en)
|
2007-09-12 |
2016-05-17 |
노파르티스 아게 |
Gas57 mutant antigens and gas57 antibodies
|
CN104292312A
(en)
|
2007-12-21 |
2015-01-21 |
诺华股份有限公司 |
Mutant forms of streptolysin o
|
US8466167B2
(en)
|
2008-03-03 |
2013-06-18 |
Irm Llc |
Compounds and compositions as TLR activity modulators
|
CN102159242A
(en)
|
2008-09-18 |
2011-08-17 |
诺华有限公司 |
Vaccine adjuvant combinations
|
ES2586308T3
(en)
|
2008-10-27 |
2016-10-13 |
Glaxosmithkline Biologicals Sa |
Purification procedure of a group A Streptococcus carbohydrate
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
AU2010203223B9
(en)
|
2009-01-05 |
2015-10-08 |
Epitogenesis Inc. |
Adjuvant compositions and methods of use
|
AU2010204139A1
(en)
|
2009-01-12 |
2011-08-11 |
Novartis Ag |
Cna_B domain antigens in vaccines against gram positive bacteria
|
US8568732B2
(en)
|
2009-03-06 |
2013-10-29 |
Novartis Ag |
Chlamydia antigens
|
ITMI20090946A1
(en)
|
2009-05-28 |
2010-11-29 |
Novartis Ag |
EXPRESSION OF RECOMBINANT PROTEINS
|
TR201802380T4
(en)
|
2009-06-10 |
2018-03-21 |
Glaxosmithkline Biologicals Sa |
Vaccines containing benzonaphthyridine.
|
ES2596653T3
(en)
|
2009-06-16 |
2017-01-11 |
Glaxosmithkline Biologicals Sa |
Opsonization bactericidal and antibody-dependent assays mediated by high-performance complement
|
JP2013503148A
(en)
|
2009-08-27 |
2013-01-31 |
ノバルティス アーゲー |
Adjuvants containing aluminum, oligonucleotides and polycations
|
TWI445708B
(en)
|
2009-09-02 |
2014-07-21 |
Irm Llc |
Compounds and compositions as tlr activity modulators
|
AU2010290896B2
(en)
|
2009-09-02 |
2014-07-03 |
Glaxosmithkline Biologicals S.A. |
Immunogenic compositions including TLR activity modulators
|
CA2779798C
(en)
|
2009-09-30 |
2019-03-19 |
Novartis Ag |
Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
JP5914344B2
(en)
|
2009-10-30 |
2016-05-11 |
ノバルティス アーゲー |
Purification of Staphylococcus aureus type 5 and type 8 capsular saccharides
|
WO2011057148A1
(en)
|
2009-11-05 |
2011-05-12 |
Irm Llc |
Compounds and compositions as tlr-7 activity modulators
|
JP5814933B2
(en)
|
2009-12-15 |
2015-11-17 |
ノバルティス アーゲー |
Homogeneous suspension of immune enhancing compounds and uses thereof
|
EP2549990A1
(en)
|
2010-03-23 |
2013-01-30 |
Irm Llc |
Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
|
WO2011133433A2
(en)
*
|
2010-04-16 |
2011-10-27 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention |
Real time pcr assay for detection of bacterial respiratory pathogens
|
SI3243526T1
(en)
|
2010-07-06 |
2020-02-28 |
Glaxosmithkline Biologicals S.A. |
Delivery of rna to trigger multiple immune pathways
|
EP2591114B1
(en)
|
2010-07-06 |
2016-06-08 |
GlaxoSmithKline Biologicals SA |
Immunisation of large mammals with low doses of rna
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
SI4005592T1
(en)
|
2010-07-06 |
2023-03-31 |
Glaxosmithkline Biologicals S.A. |
Virion-like delivery particles for self-replicating rna molecules
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
BR112013000244A2
(en)
|
2010-07-06 |
2016-05-17 |
Novartis Ag |
lipid liposomes having advantageous pka for administration of rna
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
WO2012031046A2
(en)
|
2010-08-31 |
2012-03-08 |
Novartis Ag |
Lipids suitable for liposomal delivery of protein-coding rna
|
ES2938866T3
(en)
|
2010-08-31 |
2023-04-17 |
Glaxosmithkline Biologicals Sa |
Pegylated liposomes for delivery of RNA encoding immunogen
|
CN103313725B
(en)
|
2010-09-01 |
2016-06-29 |
诺华有限公司 |
Immunostimulant absorption insoluble petal ion
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
CN104531812A
(en)
|
2010-10-01 |
2015-04-22 |
现代治疗公司 |
Engineered nucleic acids and methods of use thereof
|
ES2716243T3
(en)
|
2010-10-11 |
2019-06-11 |
Glaxosmithkline Biologicals Sa |
Antigen Supply Platforms
|
WO2012082914A1
(en)
|
2010-12-14 |
2012-06-21 |
Novartis Ag |
Flow cytometry analysis of materials adsorbed to metal salts
|
EP2655389A2
(en)
|
2010-12-24 |
2013-10-30 |
Novartis AG |
Compounds
|
EP2667852B1
(en)
|
2011-01-27 |
2016-11-09 |
GlaxoSmithKline Biologicals SA |
Adjuvant nanoemulsions with crystallisation inhibitors
|
EP2680885B8
(en)
|
2011-03-02 |
2018-07-25 |
GlaxoSmithKline Biologicals SA |
Combination vaccines with lower doses of antigen and/or adjuvant
|
WO2012129483A1
(en)
|
2011-03-24 |
2012-09-27 |
Novartis Ag |
Adjuvant nanoemulsions with phospholipids
|
WO2012135805A2
(en)
|
2011-03-31 |
2012-10-04 |
modeRNA Therapeutics |
Delivery and formulation of engineered nucleic acids
|
CA2836468C
(en)
|
2011-05-17 |
2021-05-04 |
The Rockefeller University |
Human immunodeficiency virus neutralizing antibodies and methods of use thereof
|
BR112013032410A2
(en)
*
|
2011-06-24 |
2017-01-17 |
Epitogenesis Inc |
pharmaceutical compositions comprising a combination of selection vehicles, vitamins, tannins and flavonoids as antigen specific immunomodulators
|
SG10201605537XA
(en)
|
2011-07-06 |
2016-09-29 |
Novartis Ag |
Liposomes having useful n:p ratio for delivery of rna molecules
|
EP3854413A1
(en)
|
2011-07-06 |
2021-07-28 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
DK2750707T3
(en)
|
2011-08-31 |
2019-02-11 |
Glaxosmithkline Biologicals Sa |
PEGYLED LIPOSOMES FOR DELIVERING IMMUNOGEN-CODING RNA
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
WO2013038375A2
(en)
|
2011-09-14 |
2013-03-21 |
Novartis Ag |
Methods for making saccharide-protein glycoconjugates
|
RU2707251C2
(en)
|
2011-10-03 |
2019-11-25 |
Модерна Терапьютикс, Инк. |
Modified nucleosides, nucleotides and nucleic acids and use thereof
|
AU2012335208B2
(en)
|
2011-11-07 |
2017-08-31 |
Glaxosmithkline Biologicals S.A. |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
KR20140102759A
(en)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
JP2015510872A
(en)
|
2012-03-07 |
2015-04-13 |
ノバルティス アーゲー |
Enhanced formulation of Streptococcus pneumoniae antigen
|
ES2597755T3
(en)
|
2012-03-07 |
2017-01-20 |
Glaxosmithkline Biologicals Sa |
Arginine salts of a TLR7 agonist
|
RU2014140521A
(en)
|
2012-03-08 |
2016-04-27 |
Новартис Аг |
ADJUVANT COMPOSITIONS OF BOOSTER VACCINES
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
EP2833892A4
(en)
|
2012-04-02 |
2016-07-20 |
Moderna Therapeutics Inc |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
JP2015518845A
(en)
|
2012-05-22 |
2015-07-06 |
ノバルティス アーゲー |
Neisseria meningitidis serogroup X conjugate
|
MX363529B
(en)
|
2012-09-18 |
2019-03-27 |
Novartis Ag |
Outer membrane vesicles.
|
JP6144355B2
(en)
|
2012-11-26 |
2017-06-07 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
Chemically modified mRNA
|
CN105188747A
(en)
|
2013-02-01 |
2015-12-23 |
葛兰素史密斯克莱生物公司 |
Intradermal delivery of immunological compositions comprising TOLL-like receptor agonists
|
BR112015021791B1
(en)
|
2013-03-08 |
2022-08-30 |
Novartis Ag |
CATIONIC LIPID COMPOUNDS AND LIPID AND PHARMACEUTICAL COMPOSITIONS
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
US10323076B2
(en)
|
2013-10-03 |
2019-06-18 |
Modernatx, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
ES2806575T3
(en)
|
2013-11-01 |
2021-02-18 |
Curevac Ag |
Modified RNA with decreased immunostimulatory properties
|
EP3872066A1
(en)
|
2013-12-19 |
2021-09-01 |
Novartis AG |
Lipids and lipid compositions for the delivery of active agents
|
EP3083579B1
(en)
|
2013-12-19 |
2022-01-26 |
Novartis AG |
Lipids and lipid compositions for the delivery of active agents
|
US10342761B2
(en)
|
2014-07-16 |
2019-07-09 |
Novartis Ag |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
WO2016037053A1
(en)
|
2014-09-05 |
2016-03-10 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
EP3061826A1
(en)
|
2015-02-27 |
2016-08-31 |
Novartis AG |
Flavivirus replicons
|
ES2937963T3
(en)
|
2015-07-21 |
2023-04-03 |
Modernatx Inc |
Infectious disease vaccines
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
Tropical disease vaccines
|
WO2017083337A1
(en)
*
|
2015-11-10 |
2017-05-18 |
Ohio State Innovation Foundation |
Methods and compositions related to accelerated humoral affinity
|
EP3439704A1
(en)
|
2016-04-05 |
2019-02-13 |
GSK Vaccines S.r.l. |
Immunogenic compositions
|
EP3681514A4
(en)
|
2017-09-14 |
2021-07-14 |
ModernaTX, Inc. |
Zika virus rna vaccines
|
KR20200123436A
(en)
|
2018-02-12 |
2020-10-29 |
이니뮨 코퍼레이션 |
Toll-like receptor ligand
|
IL302449A
(en)
|
2020-11-04 |
2023-06-01 |
Eligo Bioscience |
Cutibacterium acnes recombinant phages, method of production and uses thereof
|
WO2023021427A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
|
WO2023021421A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Low-dose lyophilized rna vaccines and methods for preparing and using the same
|